Phase 1 Trial of Intrathecal Azacitidine and Nivolumab in Patients With Recurrent High-grade Glioma
This early-stage study tests the safety of giving two medications, azacitidine and nivolumab, directly into the spinal fluid for patients with a fast-growing brain tumor that has returned. Researchers want to see how well patients tolerate this combination to help develop better treatment options.
This study is open to adults and teenagers aged 13 and older who have a confirmed diagnosis of a recurrent high-grade brain tumor and have already gone through standard treatments like radiation. Participants must also be healthy enough overall to follow all study rules and procedures.
Participants will receive the study medications directly into their spinal fluid, along with regular imaging scans and spinal taps to monitor their health and the tumor. The medical team will closely watch for any side effects and check how your body responds to the treatment.
The study is currently enrolling participants by invitation in Iowa City, Iowa, United States. Your care team can help you find out if a location is convenient and right for your needs.
- 1Tests two medications given directly into the spinal fluid for recurrent brain tumors.
- 2Open to patients aged 13 and older who have already tried standard treatments like radiation.
- 3Involves regular check-ups, imaging scans, and close monitoring by the medical team.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.